Date/Time: Friday, October 9, 2020 - 3:30 PM – 5:30 PM
Track: Special Interest Group
Log in to Add to My Schedule
The incidence of neurologic autoimmune disorders in the context of wider use of anti-cancer immunotherapies is increasing. Immune checkpoint inhibitors and CAR-T cells interrupt mechanisms involved in prevention of auto-immunity or have pro-inflammatory properties. As a result, a wide-ranging spectrum of neurologic inflammatory adverse events have emerged posing diagnostic and therapeutic challenges that neurologists need to address. Immunotherapies are also an area of active investigation in patients with primary brain tumors. This session will review advances in immunotherapy of primary brain tumors and discuss neurologic complications of cancer and cancer therapies. The rationale for targeting the immune system in brain tumor therapy and the results of ongoing trials will be discussed. The mechanisms underlying neurologic adverse effects, and their diagnosis and management will be reviewed.
To recognize strategies to identify and manage cancer related auto-immunity and the unique adverse events related to use of anti-CTLA-4, anti-PD-1, anti-PD-L1 antibodies and CAR-T cell therapies.
To describe the rationale for targeting the immune system in the treatment of brain tumors.
To evaluate results of ongoing clinical trials examining immunotherapy agents as part of treatment paradigms.